Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche
Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal cancer and other solid tumors.
Roche, Lilly's blood test for Alzheimer's diagnosis gets US approval
Roche Diagnostics said on Monday the U.S. Food and Drug Administration cleared its and partner Eli Lilly's blood test as an aid in the initial assessment for Alzheimer's disease.
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer.
Roche Holding AG - Special Call
Roche Holding AG - Special Call Company Participants Bruno Eschli - Head of Investor Relations Teresa Graham - Chief Executive Officer of Roche Pharmaceuticals Levi Garraway - Executive VP, Head of Global Product Development & Chief Medical Officer Charles Fuchs - Global Head of Oncology & Hematology Drug Development - Genentech & Roche Hideki Garren Larry Tsai Chris Brittain - Global Head of Ophthalmology Product Development & VP Manu Chakravarthy Conference Call Participants Richard Vosser - JPMorgan Chase & Co, Research Division Sachin Jain - BofA Securities, Research Division Matthew Weston - UBS Investment Bank, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division Michael Leuchten - Jefferies LLC, Research Division Sarita Kapila - Morgan Stanley, Research Division Emmanuel Papadakis - Deutsche Bank AG, Research Division Naresh Chouhan - Intron Health Advisors Ltd Justin Steven Smith - Sanford C.
Roche's Drug Candidate Meets Main Goals in Late-Stage Breast Cancer Study
The pharmaceutical company said that giredestrant in combination with everolimus significantly improved progression-free survival in patients with advanced breast cancer.
Roche to buy US biotech 89bio in $3.5bn deal
Roche has agreed to acquire American biotech 89bio in a transaction worth up to $3.5 billion, as it looks to expand its pipeline of treatments for liver and cardiometabolic diseases. The Swiss pharmaceutical group said the deal values 89bio at $2.4 billion upfront, with an additional $1.1 billion tied to milestone payments.
Roche to Buy 89bio for Up to $3.5 Billion
The deal seeks to strengthen the drugmaker's pipeline by adding an experimental drug for an obesity comorbidity.
Roche to acquire liver drug developer 89bio for up to $3.5 billion
Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio ETNB.O for up to $3.5 billion to strengthen its development pipeline on liver and cardiometabolic disease treatments.
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday.
Roche Holding AG (RHHBY) Q2 2025 Earnings Call Transcript
Roche Holding AG (OTCQX:RHHBY) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Alan Hippe - Chief Financial Officer Bruno Eschli - Head of Investor Relations Matthew Sause - Chief Executive Officer Teresa A. Graham - Chief Executive Officer of Roche Pharmaceuticals Thomas Schinecker - Group Chief Executive Officer Conference Call Participants Emmanuel Douglas Papadakis - Deutsche Bank AG, Research Division James Patrick Quigley - Goldman Sachs Group, Inc., Research Division Justin Steven Barrie Smith - Sanford C.
Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well
RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.
